[7] [12] However, Phase 2 trials are not powered to detect rare cardiovascular outcomes, and longer-term Phase 3 data including dedicated cardiovascular outcome trials will be essential to fully characterise the cardiac safety profile of retatrutide
This mix-up could lead to patients taking the wrong medication, posing risks such as ineffective treatment, drug interactions, or potential side effects
Then there is the future approval phase , when pricing may look more like other branded weight-loss medications
Nat Neurosci 9:119126 Shashidharan P, Huntley GW, Murray JM, Buku A, Moran T, Walsh MJ, Morrison JH, Plaitakis A (1997) Immunohistochemical localization of the neuron-specific glutamate transporter EAAC1 (EAAT3) in rat brain and spinal cord revealed by a novel monoclonal antibody